Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD, Inc. (NSPR) files reports with the U.S. Securities and Exchange Commission as a Nasdaq-listed medical device company focused on the CGuard® Prime carotid stent system and its proprietary MicroNet™ mesh technology. These SEC filings provide detailed information on the company’s financial condition, capital structure, clinical and regulatory milestones, and governance.
Current reports on Form 8-K frequently disclose key events such as quarterly financial results, private placement financings, warrant exercises, and updates to investor presentations. For example, a November 4, 2025 Form 8-K discusses financial and operating results for the quarter ended September 30, 2025, while a July 31, 2025 Form 8-K outlines a securities purchase agreement for a private placement of common stock and pre-funded warrants, as well as the full exercise of a series of warrants.
Filings also document important regulatory and commercial milestones. A June 24, 2025 Form 8-K reports that InspireMD received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States, and a July 9, 2025 Form 8-K references a press release announcing the U.S. commercial launch of CGuard® Prime. Other 8-Ks describe changes to the board of directors, including the appointment of independent directors and audit committee chairs, and amendments that specify committee assignments.
On this page, users can review InspireMD’s Forms 8-K and related exhibits, along with other periodic reports when available. Stock Titan adds AI-powered summaries that explain the main points of lengthy filings, highlight material agreements and capital-raising terms, and surface notable disclosures about clinical and regulatory developments. Investors and researchers can use these NSPR filings to understand how InspireMD reports its progress in carotid stenting, manages its capital resources, and addresses the risks and uncertainties outlined in its forward-looking statements.
InspireMD's new Chief Financial Officer Michael Lawless filed an initial Form 3 statement disclosing his beneficial ownership position upon appointment. The filing reveals two key components of his compensation package:
- 465,000 restricted stock shares vesting in three equal annual installments of 155,000 shares each on June 25, 2026, 2027, and 2028
- 212,000 stock options with an exercise price of $2.24, vesting similarly in three equal annual installments through 2028
All equity awards are contingent on Lawless's continued service with the company. This initial beneficial ownership disclosure, filed within the required timeline following his appointment, demonstrates a significant equity-based compensation structure aligned with long-term shareholder interests through the extended vesting schedule.
InspireMD has received FDA Premarket Approval (PMA) for its CGuard Prime Carotid Stent System on June 23, 2025, marking a significant regulatory milestone. This approval follows their PMA application submitted on September 16, 2024.
Key developments include:
- FDA PMA approval for stroke prevention device
- Release of updated investor presentation available on company website
- Trading on Nasdaq Capital Market under symbol NSPR
The company issued a press release on June 24, 2025, announcing the approval. The filing includes two key exhibits: the press release and an updated investor presentation. This regulatory achievement potentially opens up the U.S. market for InspireMD's carotid stent system, representing a material development for the company's commercial prospects.